Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.58 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.58 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21551996 | 0.91 | DYRK1A (0.61) | DYRK1ADYRK1BNSD2RAB9ANPC1 | |
| SCHEMBL23256883 | 0.91 | DYRK1A (0.66) | DYRK1ADYRK1BNSD2RAB9ANPC1 | |
| SCHEMBL21568167 | 0.87 | MEN1 (0.60) | DYRK1ADYRK1BNSD2RAB9ANPC1 | |
| SCHEMBL23256882 | 0.87 | DYRK1A (0.58) | DYRK1ADYRK1BNSD2RAB9ANPC1 | |
| SCHEMBL23256872 | 0.87 | HSD17B10 (0.61) | DYRK1ADYRK1BNSD2RAB9ANPC1 | |
| SCHEMBL21568324 | 0.87 | DYRK1A (0.58) | DYRK1ADYRK1BNSD2RAB9ANPC1 | |
| SCHEMBL21568137 | 0.86 | MAPT (0.68) | DYRK1ADYRK1BNSD2RAB9ANPC1 | |
| SCHEMBL31637674 | 0.86 | HSD17B10 (0.61) | DYRK1ADYRK1BNSD2RAB9ANPC1 | |
| SCHEMBL21568954 | 0.86 | DYRK1A (0.66) | DYRK1ADYRK1BNSD2RAB9ANPC1 | |
| SCHEMBL21568123 | 0.85 | DYRK1A (0.65) | DYRK1ADYRK1BRAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2019217509-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | DYRK1A 4664/4885DYRK1B 4707/4885NSD2 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.